teneligliptin teneligliptin teneligliptin (inn; trade name tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. it belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins". teneligliptinclinical datatrade namesteneliaatc codea10bh08 (who) legal statuslegal status approved in japan identifiers iupac name (1,3-thiazolidin-3-yl)methanone cas number760937-92-6pubchem cid11949652chemspider10123963unii28zhi4cf9ccomptox dashboard (epa)dtxsid30997419 chemical and physical dataformulac22h30n6osmolar mass426.58 g·mol−13d model (jsmol)interactive image smiles cc1=nn(c(=c1)n2ccn(cc2)3c(nc3)c(=o)n4ccsc4)c5=cc=cc=c5 inchi inchi=1s/c22h30n6os/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23h,7-12,14-16h2,1h3/t19-,20-/m0/s1key:wgrqanopcqrcme-pmacekpbsa-n creation it was created by mitsubishi tanabe pharma and launched in september 2012 by both mitsubishi tanabe pharma and daiichi sankyo in japan. licensing and use japan/korea/india/argentina it is approved for use in japan, argentina, korea and india. pharmacology teneligliptin has unique j shaped or anchor locked domain structure because of which it has a potent inhibition of dpp 4 enzyme. teneligliptin significantly controls glycemic parameters with safety. no dose adjustment is required in renally impaired patients.